Physician profile
Toby B Okons
NPI 1407998990
$3,582.53
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $342 · 2021: $923 · 2022: $779 · 2023: $582 · 2024: $61.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,179.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $779.86 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $395.92 | 2020-2023 | Rybelsus, Ozempic |
| Allergan, INC. | $210.09 | 2019-2020 | |
| Amgen INC. | $149.45 | 2019-2023 | Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $134.54 | 2021-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.01 | 2022 | |
| Abbvie INC. | $78.79 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $48.44 | 2021-2022 | |
| Pfizer INC. | $46.17 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.68 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.04 | 2021-2024 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $26.05 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.03 | 2019-2021 | |
| Shield Therapeutics INC | $22.18 | 2024 | |
| Inspire Medical Systems, INC. | $18.89 | 2023 | Inspire |
| Avanir Pharmaceuticals, INC. | $17.96 | 2022 | |
| Abbott Laboratories | $16.92 | 2022 | |
| Kaleo, INC. | $16.21 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.09 | 2023 | Linzess |
| Eyevance Pharmaceuticals LLC | $13.88 | 2021 | |
| Hikma Pharmaceuticals USA | $13.88 | 2021 | |
| Biodelivery Sciences International, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Okons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.